LNC

Matinas BioPharma Prices $10 Million Registered Direct Offering

Retrieved on: 
Wednesday, April 3, 2024
Form, Prospectus, LNC, File, Sale, Madison Avenue, S-3, Security (finance)

The gross proceeds of the offering will be approximately $10 million before deducting fees and other estimated offering expenses.

Key Points: 
  • The gross proceeds of the offering will be approximately $10 million before deducting fees and other estimated offering expenses.
  • The closing of the offering is expected to take place on or about April 5, 2024, subject to the satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
  • A final prospectus supplement and accompanying base prospectus relating to the offering will be filed by Matinas BioPharma with the SEC.

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

Retrieved on: 
Monday, March 25, 2024
Toxicity, Therapeutic index, Conference, Human, Docetaxel, Webcast, Weight loss, LNC, Neoplasm, Mouse, Calendar, Melanoma, Lecture, Pharmaceutical industry

BEDMINSTER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces positive results from an additional in vivo study in healthy mice with an oral LNC formulation of docetaxel, a well-established chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors. Docetaxel is currently only administered intravenously and is frequently associated with significant side effects and treatment-limiting toxicities.

Key Points: 
  • "These recent data show how our oral LNC-docetaxel formulation can dramatically reduce the well-recognized toxicity of IV-docetaxel, as primarily manifested by weight loss in this model,” said James J. Ferguson, M.D., Chief Medical Officer of Matinas .
  • We have now corroborated this lack of toxicity in a more comprehensive safety study with a longer treatment duration and even higher doses of oral LNC-docetaxel.
  • Mice treated with oral LNC-docetaxel maintained their body weight, which was statistically no different than the weight of control mice treated with oral saline.
  • The webcast will be available on the IR Calendar page of the Matinas website and will be archived for six months.

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Retrieved on: 
Friday, March 22, 2024
Nephrotoxicity, Urinary tract infection, Fungal infection, Culture, Ventilator-associated pneumonia, Burns, Internal medicine, Amphotericin B, Emphysema, Azole, Coronary artery disease, Debridement, Carcinoma, Risk, Hyperlipidemia, Patient, Lung, LNC, Fusarium, Female, Malignancy, University, Doctor of Philosophy, MD, Aspergillosis, Echinocandin, Fever, Immune system, Division, Hypertension, Voriconazole, Physician, Infection, Pharmaceutical industry

The successful MAT2203 treatment outcome in these patients therefore adds to our confidence for the upcoming ORALTO Phase 3 trial in patients suffering from invasive aspergillosis with limited treatment options.

Key Points: 
  • The successful MAT2203 treatment outcome in these patients therefore adds to our confidence for the upcoming ORALTO Phase 3 trial in patients suffering from invasive aspergillosis with limited treatment options.
  • She was transitioned to oral MAT2203 for two weeks, which led to clinical resolution of her fungal infection.
  • She began to show clinical improvement following two weeks of oral MAT2203 treatment and her skin wounds completely healed following six months of MAT2203 treatment.
  • “MAT2203 continues to demonstrate its potential to effectively treat invasive fungal infections and help patients achieve complete clinical resolution.

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Retrieved on: 
Friday, March 22, 2024
LNC

BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced that on March 21, 2024, the Company received written notification from the NYSE American LLC ("NYSE American") stating that the Company has regained compliance with the NYSE American’s continued listing standards.

Key Points: 
  • BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced that on March 21, 2024, the Company received written notification from the NYSE American LLC ("NYSE American") stating that the Company has regained compliance with the NYSE American’s continued listing standards.
  • Specifically, the Company has resolved the continued listing deficiency with respect to the low selling price of its common stock as described in Section 1003(f)(v) of the NYSE American Company Guide due to shares of its common stock demonstrating sustained price improvement.
  • In the notification, the NYSE American informed the Company that the below compliance (".BC") indicator will no longer be disseminated at the opening of trading on March 22, 2024, and the Company will be removed from the NYSE American noncompliant issuers list on the NYSE American's website.

Lincoln Financial Group to Report 2024 First Quarter Results on May 2

Retrieved on: 
Thursday, April 4, 2024
Banking, Professional Services, Insurance, Finance, Webcast, Lincoln National Corporation, LNC, Conference call, Conference, Flour

Lincoln Financial Group (NYSE:LNC) announced today that it will report its results for the first quarter ended March 31, 2024 at 7:00 a.m. Eastern Time on Thursday, May 2, 2024.

Key Points: 
  • Lincoln Financial Group (NYSE:LNC) announced today that it will report its results for the first quarter ended March 31, 2024 at 7:00 a.m. Eastern Time on Thursday, May 2, 2024.
  • Earnings materials, including the 2024 first quarter Earnings Release and Statistical Supplement, will be available on the company’s Investor Relations web page at www.lincolnfinancial.com/investor .
  • A replay of the webcast will be available at www.lincolnfinancial.com/webcast by 10:00 a.m. Eastern Time on May 2, 2024.
  • Anticipated future earnings release and conference call dates & times:
    Second Quarter 2024 – August 1, 2024
    Earnings release at 7:00 a.m. Eastern Time
    Conference call at 8:00 a.m. Eastern Time
    Third Quarter 2024 – October 31, 2024
    Earnings release at 7:00 a.m. Eastern Time
    Conference call at 8:00 a.m. Eastern Time
    Fourth Quarter and Full Year 2024 – February 6, 2025
    Earnings release at 7:00 a.m. Eastern Time
    Conference call at 8:00 a.m. Eastern Time

Lincoln Financial Group Introduces Side-by-Side Pooled Employer Retirement Solutions for Businesses and Not-for-Profit Organizations

Retrieved on: 
Wednesday, April 3, 2024
Banking, Personal Finance, Professional Services, Finance, Research, Lincoln, Lincoln National Corporation, Organization, Exhibit, LNC, Envestnet, Small business, PEPS, Retirement, PEP, Bureau of Labor Statistics, Financial adviser

Lincoln Financial Group (NYSE:LNC) announces the launch of FlexPEP(k) and FlexPEP(b), comprehensive pooled employer plans (PEP) for 401(k) and 403(b) plans, respectively.

Key Points: 
  • Lincoln Financial Group (NYSE:LNC) announces the launch of FlexPEP(k) and FlexPEP(b), comprehensive pooled employer plans (PEP) for 401(k) and 403(b) plans, respectively.
  • These tailored solutions add to Lincoln’s lineup of group plan solutions totaling more than $1.3 billion in assets.
  • “We’re seeing an uptick in the adoption of group plan solutions as employers look to streamline their retirement plan administration, minimize costs and enhance fiduciary protection,” said Matt Condos, senior vice president, Retirement Plan Services Product Solutions, Lincoln Financial Group.
  • For more information about Lincoln’s full suite of retirement solutions, including OpenPEP , visit our group retirement plan pages for employers and financial professionals .

Lincoln Financial Study Finds Inflation Is the Number One Financial Concern Among Consumers of Every Generation

Retrieved on: 
Tuesday, April 2, 2024
Personal Finance, Finance, Consulting, Professional Services, Insurance, Lincoln, Millennials, Lincoln National Corporation, Tax, Education, LNC, Life, Thought, Identity theft, Infant, Fraud, Retirement, Family, Financial Literacy Month, Conditional sentence

The study revealed that inflation is the top cited financial concern (66%) among American consumers across every generation.

Key Points: 
  • The study revealed that inflation is the top cited financial concern (66%) among American consumers across every generation.
  • Despite the focus on inflation, few are taking action to combat it – even among those who work with a financial professional.
  • Only 17% of respondents who cited inflation as a concern have recently sought advice about how to address their concern.
  • “We see a clear opportunity for advisors to address consumers’ top financial concerns head on with their clients.

Lincoln Financial Group Recognized by DALBAR for Consumer Experience

Retrieved on: 
Tuesday, March 26, 2024
Professional Services, Insurance, Finance, Lincoln, Lincoln National Corporation, LNC

Lincoln Financial Group (NYSE:LNC) announced today that it has been recognized by DALBAR, Inc. , for excellence in its annuity illustrations and its life insurance website experience.

Key Points: 
  • Lincoln Financial Group (NYSE:LNC) announced today that it has been recognized by DALBAR, Inc. , for excellence in its annuity illustrations and its life insurance website experience.
  • DALBAR is a preeminent auditor of consumer experience for the financial services industry.
  • The recognition marks the fifth consecutive year that Lincoln has received DALBAR’s Award for Excellence in Annuity Illustrations, following its review of 17 illustration categories across 11 leading annuity firms.
  • “Lincoln is honored to be selected by DALBAR, an expert in the field, for our continued commitment to providing an exceptional experience for consumers and financial professionals.”

AM Best Assigns Issue Credit Rating to Lincoln National Corporation’s New Senior Unsecured Notes

Retrieved on: 
Friday, March 15, 2024
Insurance, Professional Services, Risk, LNC, ALL, Lincoln National Corporation, Sale, News, Long-Term Capital Management, Credit, Credit rating, AM Best, Good, Bank

AM Best has assigned a Long-Term Issue Credit Rating (Long-Term IR) of “bbb+” (Good) to the $350 million 5.852% senior unsecured notes, due March 15, 2034, issued by Lincoln National Corporation (LNC) (headquartered in Radnor, PA).

Key Points: 
  • AM Best has assigned a Long-Term Issue Credit Rating (Long-Term IR) of “bbb+” (Good) to the $350 million 5.852% senior unsecured notes, due March 15, 2034, issued by Lincoln National Corporation (LNC) (headquartered in Radnor, PA).
  • LNC’s existing Long-Term Issuer Credit Rating and Long-Term IRs remain unchanged.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry.

Lincoln Financial Group Enhances Its Fixed Indexed Annuities With Innovative Crediting Strategies

Retrieved on: 
Wednesday, March 13, 2024
Banking, Professional Services, Finance, Trigger, Retirement, Lincoln, S&P, Lincoln National Corporation, LNC, Growth, Investment

Lincoln Financial fixed indexed annuities offer a variety of crediting strategies to support individuals’ unique investing goals.

Key Points: 
  • Lincoln Financial fixed indexed annuities offer a variety of crediting strategies to support individuals’ unique investing goals.
  • As this historic surge reaches retirement age, Lincoln Financial is committed to helping investors protect their hard-earned savings,” said Tim Seifert, senior vice president and head of Retirement Solutions Distribution at Lincoln Financial Group.
  • In 2023, Lincoln Financial worked with over 22,000 financial professionals to provide new annuity contracts to clients.
  • For more information about Lincoln Financial fixed indexed annuities, visit: https://www.lincolnfinancial.com/public/individuals/products/annuities/f...